Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 40 articles: HTML format

Single Articles

November 2025
1. SHEN QM, Li ZY, Wang J, Zou YX, et al
   Prediagnostic plasma metabolite concentrations and liver cancer risk: A nested case-control study with long follow-up in the Shanghai Women's Health Study.
   Int J Cancer. 2025;157:1805-1817.
   PubMed     Abstract available
   
   
   
2. SHEN Q, Shi S, Wang H, Zhang S, et al
   Serum 25-hydroxyvitamin D, vitamin D-related variants, and risk of chronic liver disease.
   Int J Cancer. 2025;157:1781-1794.
   PubMed     Abstract available
   
   
   October 2025
3. YANG Z, Wang L, Kang F
   Immunogenic cell death: A promising mechanism involving different therapeutic strategies for liver cancer.
   Int J Cancer. 2025;157:1267-1276.
   PubMed     Abstract available
   
   
   September 2025
4. VAN DER GEEST LG, van der Mark M, Verheij J, Farina Sarasqueta A, et al
   Increased incidence, survival, and registration quality of primary hepato-pancreato-biliary cancers in the Netherlands Cancer Registry.
   Int J Cancer. 2025 Sep 12. doi: 10.1002/ijc.70145.
   PubMed     Abstract available
   
   
   August 2025
5. GUERRERO JJG, Encarnacion PC, Del Rosario MAS, Ora MAS, et al
   Genetic variants underlying precancerous conditions of hepatocellular carcinoma.
   Int J Cancer. 2025 Aug 20. doi: 10.1002/ijc.70092.
   PubMed     Abstract available
   
   
   
6. ZHAO L, Cheng J, Zheng Y, Wu J, et al
   Targeting aerobic glycolysis combats tyrosine kinase inhibitor resistance of hepatocellular carcinoma.
   Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70091.
   PubMed     Abstract available
   
   
   July 2025
7. HUANG F, Jiang H, Shen M, Zhang C, et al
   Plasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction.
   Int J Cancer. 2025 Jul 22. doi: 10.1002/ijc.70055.
   PubMed     Abstract available
   
   
   
8. AIELLO C, Felli E, Musarra T, Nevi L, et al
   Rewriting the MASLD-associated hepatocellular carcinoma script: Targeting epigenetics and metabolism.
   Int J Cancer. 2025 Jul 22. doi: 10.1002/ijc.70047.
   PubMed     Abstract available
   
   
   
9. PHAM YT, Wang R, Behari J, Chen GC, et al
   Plant-based diet index and risk of hepatocellular carcinoma: Findings from a prospective cohort study.
   Int J Cancer. 2025 Jul 19. doi: 10.1002/ijc.70057.
   PubMed     Abstract available
   
   
   
10. YU C, Lin F, Tian C, Guo H, et al
    Baseline vitamin D status, genetic susceptibility, and the risk of incident hepatocellular carcinoma.
    Int J Cancer. 2025 Jul 3. doi: 10.1002/ijc.70003.
    PubMed     Abstract available
    
    
    June 2025
11. PASSEN CV, Krug J, Weiss L, Abdou MM, et al
    Integrin beta6 expression in colorectal cancer cells promotes liver metastasis through enhanced adhesion to endothelial fibronectin.
    Int J Cancer. 2025 Jun 9. doi: 10.1002/ijc.35504.
    PubMed     Abstract available
    
    
    May 2025
12. PATEL DP, Loffredo CA, Pupacdi B, Rabibhadana S, et al
    Associations of chronic liver disease and liver cancer with glyphosate and its metabolites in Thailand.
    Int J Cancer. 2025;156:1885-1897.
    PubMed     Abstract available
    
    
    March 2025
13. AGLAGO EK, Ramos I, Keski-Rahkonen P, Chatziioannou C, et al
    Alcohol and smoking habits in association with hepatocellular carcinoma risk.
    Int J Cancer. 2025 Mar 18. doi: 10.1002/ijc.35401.
    PubMed     Abstract available
    
    
    
14. GAO Y, Cheng AL, Li LX, Parent N, et al
    Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.
    Int J Cancer. 2025 Mar 13. doi: 10.1002/ijc.35407.
    PubMed     Abstract available
    
    
    
15. JIANG X, Zhang Q, Zheng Z, Shen Z, et al
    Latent class analysis-derived classification for cancer-specific death stratification of hepatocellular carcinoma.
    Int J Cancer. 2025 Mar 12. doi: 10.1002/ijc.35399.
    PubMed     Abstract available
    
    
    
16. CHIVITE-LACABA M, Justo I, Utrero-Rico A, Caso O, et al
    Delineation of monocytic and early-stage myeloid-derived suppressor cells in the peripheral blood of patients with hepatocarcinoma.
    Int J Cancer. 2025 Mar 7. doi: 10.1002/ijc.35390.
    PubMed     Abstract available
    
    
    January 2025
17. HE M, Xie W, Yuan Z, Chen J, et al
    Comparing PD-L1 and PD-1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresetable hepatocellular carcinoma: A single-center, real-world study.
    Int J Cancer. 2025 Jan 20. doi: 10.1002/ijc.35341.
    PubMed     Abstract available
    
    
    December 2024
18. HUANG M, Song C, Zhou X, Wang H, et al
    Tissue-matched analysis of MRI evaluating the tumor infiltrating lymphocytes in hepatocellular carcinoma.
    Int J Cancer. 2024 Dec 5. doi: 10.1002/ijc.35281.
    PubMed     Abstract available
    
    
    
19. REMOND M, Smolenschi C, Tarabay A, Gelli M, et al
    Clinical and molecular features of early onset pancreatic adenocarcinoma.
    Int J Cancer. 2024;155:1969-1981.
    PubMed     Abstract available
    
    
    November 2024
20. TRAILIN A, Ali E, Ye W, Pavlov S, et al
    Prognostic assessment of T-cells in primary colorectal cancer and paired synchronous or metachronous liver metastasis.
    Int J Cancer. 2024 Nov 7. doi: 10.1002/ijc.35252.
    PubMed     Abstract available
    
    
    
21. WATLING CZ, Kelly RK, Watts EL, Graubard BI, et al
    Total testosterone, sex hormone-binding globulin, and free testosterone concentrations and risk of primary liver cancer: A prospective analysis of 200,000 men and 180,000 postmenopausal women.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35244.
    PubMed     Abstract available
    
    
    October 2024
22. LIU J, Zhang X, Lin J, Dai C, et al
    HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy.
    Int J Cancer. 2024 Oct 25. doi: 10.1002/ijc.35224.
    PubMed     Abstract available
    
    
    September 2024
23. HO NT, Abe SK, Rahman MS, Islam R, et al
    Diabetes is associated with increased liver cancer incidence and mortality in adults: A report from Asia Cohort Consortium.
    Int J Cancer. 2024;155:854-870.
    PubMed     Abstract available
    
    
    August 2024
24. HUANG H, Zhao Y, Deng Y, Zhan Z, et al
    Optimal therapeutic strategies for hepatic metachronous oligometastatic nasopharyngeal carcinoma: Insights from a retrospective study.
    Int J Cancer. 2024 Aug 26. doi: 10.1002/ijc.35139.
    PubMed     Abstract available
    
    
    
25. BUI TT, Park E, Kang HY, Oh JK, et al
    Combined effects of smoking and alcohol consumption on the risk of liver cancer according to metabolic syndrome: A nested case-control study in South Korea.
    Int J Cancer. 2024;155:654-665.
    PubMed     Abstract available
    
    
    July 2024
26. VAZ J, Jepsen P, Stromberg U, Midlov P, et al
    Metabolic dysfunction-associated steatotic liver disease has become the most common cause of hepatocellular carcinoma in Sweden: A nationwide cohort study.
    Int J Cancer. 2024 Jul 17. doi: 10.1002/ijc.35097.
    PubMed     Abstract available
    
    
    June 2024
27. ZHAO L, Zhang X, Birmann BM, Danford CJ, et al
    Pre-diagnostic plasma inflammatory proteins and risk of hepatocellular carcinoma in three population-based cohort studies from the United States and the United Kingdom.
    Int J Cancer. 2024 Jun 11. doi: 10.1002/ijc.35054.
    PubMed     Abstract available
    
    
    
28. KARA-ALI GH, Cano L, Dion S, Imerzoukene G, et al
    Trim21 deficiency in mice increases HCC carcinogenesis in a NASH context and is associated with immune checkpoint upregulation.
    Int J Cancer. 2024;154:1999-2013.
    PubMed     Abstract available
    
    
    May 2024
29. PUPACDI B, Loffredo CA, Budhu A, Rabibhadana S, et al
    The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand.
    Int J Cancer. 2024 May 18. doi: 10.1002/ijc.35034.
    PubMed     Abstract available
    
    
    
30. GERBER TS, Ridder DA, Goeppert B, Brobeil A, et al
    N-cadherin: A diagnostic marker to help discriminate primary liver carcinomas from extrahepatic carcinomas.
    Int J Cancer. 2024;154:1857-1868.
    PubMed     Abstract available
    
    
    February 2024
31. QIN XY, Shirakami Y, Honda M, Yeh SH, et al
    Serum MYCN as a predictive biomarker of prognosis and therapeutic response in the prevention of hepatocellular carcinoma recurrence.
    Int J Cancer. 2024 Feb 21. doi: 10.1002/ijc.34893.
    PubMed     Abstract available
    
    
    
32. YU Z, Bai X, Zhou R, Ruan G, et al
    Differences in the incidence and mortality of digestive cancer between Global Cancer Observatory 2020 and Global Burden of Disease 2019.
    Int J Cancer. 2024;154:615-625.
    PubMed     Abstract available
    
    
    
33. XU FQ, Xu QY, Zhu ZJ, Jin L, et al
    Visceral and ectopic fat are more predictively associated with primary liver cancer than overall obesity from genetic sights: A Mendelian randomization study.
    Int J Cancer. 2024;154:530-537.
    PubMed     Abstract available
    
    
    
34. JIANG L, Zhao N, Xu M, Pei J, et al
    Incidence trends of primary liver cancer in different geographical regions of China from 1978 to 2012 and projections to 2032: An age-period-cohort analysis.
    Int J Cancer. 2024;154:465-476.
    PubMed     Abstract available
    
    
    
35. BARUPAL DK, Ramos ML, Florio AA, Wheeler WA, et al
    Identification of pre-diagnostic lipid sets associated with liver cancer risk using untargeted lipidomics and chemical set analysis: A nested case-control study within the ATBC cohort.
    Int J Cancer. 2024;154:454-464.
    PubMed     Abstract available
    
    
    January 2024
36. ZHAO G, Shi X, Zhang L, Liang H, et al
    Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34796.
    PubMed    
    
    
    
37. KIM MN, Zhang X, Ahn SH
    Reply to: Comments on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
    Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34797.
    PubMed    
    
    
    November 2023
38. ROSSARI F, Tada T, Suda G, Shimose S, et al
    alpha-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
    Int J Cancer. 2023 Nov 23. doi: 10.1002/ijc.34799.
    PubMed     Abstract available
    
    
    October 2023
39. SOMMERHAUSER G, Karthaus M, Kurreck A, Ballhausen A, et al
    Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212).
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34760.
    PubMed     Abstract available
    
    
    
40. SIRIRUNGREUNG A, Lee PC, Hu YH, Liew Z, et al
    Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population-based cohort study in Taiwan, 2004 to 2015.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34744.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.